Nestle Health Science Plans Continuum Of Care
This article was originally published in The Tan Sheet
Nestle's announcement that its Health Science division is buying gastrointestinal drug developer and diagnostics firm Prometheus Laboratories takes the food company in a new direction, raising questions about Nestle's possible pharmaceutical play.
You may also be interested in...
Nestle takes stake in constipation cure firm
Nestle Health Science adds gastrointestinal diagnostic services to its nutritional health business with its Prometheus Laboratories acquisition.
Nestle will invest $500 million in the next 10 years to expand its medical nutrition business and help "pioneer a new industry between food and pharma" that the firm's executives estimate will be worth $100 billion to $150 billion